A 100% tariff on patented pharmaceutical imports takes effect July 31 for 17 named companies—including Eli Lilly, Pfizer, and Novo Nordisk—with all other pharmaceutical companies facing the same rate starting September 29, per an executive order signed Thursday by President Trump.

For compliance engineering teams, this Section 232 action introduces a multi-layered conditional rate structure that will require significant updates to tariff logic and rate-caching systems. The duty calculation now depends on four intersecting factors: the importing company's identity, country of origin, HHS/Commerce agreement status, and product classification exemptions.

Tiered Country Rates

The baseline 100% rate applies only to countries without bilateral agreements. Reduced rates break down as follows:

  • 15%: European Union, Japan, South Korea, Switzerland, Liechtenstein
  • 10%: United Kingdom (potentially reducible to zero under a future pharmaceutical pricing agreement)

UK pharmaceuticals carry a separate exemption from Section 232 tariffs entirely from January 1, 2026 through January 19, 2029, per a bilateral agreement documented by USTR on Thursday.

The zero-tariff pathway introduces dual-agency logic. Companies that execute both a Most Favored Nation pricing agreement with the Department of Health and Human Services and an onshoring agreement with the Commerce Department qualify for a 0% rate through January 20, 2029. Companies with only a Commerce onshoring agreement—but no HHS pricing deal—face a 20% tariff that escalates to 100% over four years.

Product-Level Exemptions

Systems must flag the following categories as exempt from the new pharmaceutical tariffs:

  • Orphan drugs
  • Animal-health drugs (from trade-deal countries or meeting urgent public health needs)
  • Generic pharmaceuticals
  • Biosimilars
  • Associated ingredients for exempt products

Note: The White House fact sheet indicates the generic and biosimilar exemption will be reassessed in one year, creating a potential rate change trigger for Q2 2027.

Implementation requires tracking the named-company list separately from the general pharmaceutical classification. The 17 companies facing July 31 enforcement constitute a discrete lookup table; all others fall under the September 29 effective date. Rate engines must support company-level overrides layered on top of HTS-based country and product logic.

In a separate but related proclamation, Trump adjusted Section 232 tariffs on derivative steel, aluminum, and copper goods—reducing rates from 50% to 25% effective April 6. Pure metal goods remain at 50%, but derivative products (along with UK imports, goods containing U.S. steel, and certain industrial/electrical grid equipment) now require updated rate assignments in classification systems.

For teams managing HTS data pipelines, this pharmaceutical action demands immediate schema updates: company identifiers, agreement-status flags, and product exemption markers must all feed into tariff rate calculations. The staggered effective dates—July 31, September 29, and the January 2029 agreement sunset—require date-aware rate versioning.

TradeFacts.io tracks these changes nightly. Start a free 30-day trial.